Shenzhen Neptunus Interlong Bio-technique Company Limited (stock code: 8329) announced that it entered into a new sales framework agreement with Shenzhen Neptunus Group Company Limited, effective from 1 January 2026 to 31 December 2028. This agreement renews a prior arrangement set to expire on 31 December 2025, enabling continued sales of the company’s self-manufactured or distributed pharmaceutical and related products to Neptunus Group.

According to the announcement, historical sales to Neptunus Group were reported as approximately RMB41.60 million in 2023, RMB43.23 million in 2024, and RMB33.40 million for the first nine months of 2025. The proposed annual caps under the new agreement are RMB56.00 million for 2026, RMB62.00 million for 2027, and RMB69.00 million for 2028. Pricing will remain on terms no more favorable than those offered to independent parties, with settlement generally required within 60 days. The company stated that this arrangement aims to expand product sales and revenues. The new framework will be put to a vote at an extraordinary general meeting scheduled for 23 December 2025.